SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein that targets programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β). This compound is designed to enhance anti-tumor immunity by concurrently inhibiting immune checkpoint pathways and modulating the tumor microenvironment. SHR-1701 is valuable for research applications focused on cancer immunotherapy and the modulation of TGF-β signaling in various malignancies.
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein that targets programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β). This compound is designed to enhance anti-tumor immunity by concurrently inhibiting immune checkpoint pathways and modulating the tumor microenvironment. SHR-1701 is valuable for research applications focused on cancer immunotherapy and the modulation of TGF-β signaling in various malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
